BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

Benzinga · 1d ago
BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.